狄诺塞麦去哪买的到呢？

Where can I buy it? On May 28, 2010, the European Commission approved denosumab for the treatment of bone loss associated with hormone suppression in postmenopausal women with osteoporosis and prostate cancer. It can also be used in patients who are currently ineffective or intolerant to other treatments to reduce the risk of fractures. Denosumab was approved for the first time in 27 EU member states. In June of the same year, denosumab was approved by the FDA for marketing. In 2013, the FDA approved a new indication for Xgeva (denosumab) for the treatment of adult patients and skeletally mature adolescent patients with giant cell tumor of bone (GCTB) that is unresectable or whose surgical resection may cause severe complications. The drug is also the first and only GCTB treatment drug approved by the FDA. In May 2019, denosumab was conditionally approved for marketing in the country.

Denosumab is a prescription drug, and patients can buy denosumab with a prescription.

Denosumab is the first approved monoclonal antibody that specifically targets RANK ligand. RANK ligand is a transmembrane or soluble protein that is necessary for osteoclasts to maintain their structure, function, and survival. The safety of denosumab was also evaluated in a 4-year randomized, placebo-controlled phase II clinical trial. In this trial, the incidence of total adverse reactions and the incidence of serious adverse reactions in the treatment group were not significantly different from those in the placebo and alendronate groups. But the trial reported that serious infections requiring hospitalization occurred in 3.2% of the treatment group, compared with none in the placebo or alendronate groups.

In two other clinical trials, the incidence rate of osteonecrosis of the jaw was 1.1% to 2.0%, which may be related to the larger dosage in these two trials. Other adverse effects that require attention include hypocalcemia and mineral metabolism imbalance. In addition, denosumab is a humanized monoclonal antibody and may cause immunogenicity with long-term use.